The goal of this observational study is to describe a new disease condition of histiocytosis related to injecting drug use, its preconditions, symptoms, signs, findings, and prognosis in a detailed and systematic patient series in one referral center. The main question\[s\] it aims to answer are: * to find specific histologic features in different tissues to help the differential diagnosis from other histiocytoses * to describe the value of chitotriosidase activity to screen this condition * to describe the value of various tissue biopsies in confirming the diagnosis * to describe the nature of polyvinylpyrrolidone accumulation in tissue macrophages by novel special microscopic techniques * to find new tandem mass spectrometry methodology to prove polyvinylpyrrolidone accumulation in macrophages * to show that polyvinylpyrrolidone treatment activates macrophages to histiocytes and causes povidone accumulation within the cells in in vitro experiments * to evaluate the pathology of macrophage activation to histiocytes by transcriptomics The patient history will be collected from the data produced by follow-up of cases followed up in a single center. A subgroup of participants will be given an opportunity to sign informed consent to give access to/donate blood and tissue samples to search for techniques to prove polyvinylpyrrolidone storage within histiocytes, and to search for transcriptomics signal(s) in histiocytes. Researchers will compare blood and tissue samples from the biobank as controls.
Comprehensive patient data (disease history, findings, complications, laboratory findings, histopathology, and imaging) will be obtained from patient records of a single university hospital. Coded histiocytosis-positive tissue samples will be compared to biobank samples from corresponding tissues from healthy and other histiocytosis tissue samples to show polyvinylpyrrolidone storage with novel methodologies. In addition, if a study participant who is followed up clinically, signs informed consent, monocytes are separated from a blood sample, differentiated to macrophages, and exposed to polyvinylpyrrolidone. Various novel methods will be utilized to explore polyvinylpyrrolidone within histiocytes.
Study Type
OBSERVATIONAL
Enrollment
30
The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
Tampere University Hospital
Tampere, Pirkanmaa, Finland
Frequency of disease manifestations
To describe phenotype
Time frame: 10 years
Frequency of elevated chitotriosidase activity
Is chitotriosidase activity associated with polyvinylpyrrolidone histiocytosis
Time frame: 10 years
Mortality
Mortality
Time frame: 10 years
Microscopic fluorescence positive tissue
Search for specific polyvinylpyrrolidone fluorescence signal
Time frame: 10 years
Scanning electron microscope with energy-dispersive X-ray spectroscopy
search for specific polyvinylpyrrolidone signal within cells
Time frame: 10 years
Pyrolysis mass spectrometry
search for specific polyvinylpyrrolidone signal within cells
Time frame: 10 years
Transcriptomics analysis
Search for immunologic pathway-specific abnormalities to guide treatment in cases compared with controls
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.